Geron gains after GRNOPC1 hold lifted

Geron Corp. (NASDAQ:GERN) rose $0.83 (17%) to $5.63 on Friday after FDA lifted the clinical hold on an IND for a U.S. Phase I trial of GRNOPC1 to treat acute spinal cord injury. The trial for the huma...